Cambiar Investors LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 534,073 shares of the company’s stock after selling 16,477 shares during the period. Cambiar Investors LLC owned 0.05% of Eli Lilly and worth $43,954,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in LLY. Ronna Sue Cohen raised its stake in shares of Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock worth $203,000 after purchasing an additional 9 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after acquiring an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC grew its holdings in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after acquiring an additional 19 shares in the last quarter. Pillar Pacific Capital Management LLC grew its holdings in shares of Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after acquiring an additional 20 shares in the last quarter. Finally, Guardian Life Insurance Co. of America grew its holdings in shares of Eli Lilly and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock valued at $315,000 after acquiring an additional 25 shares in the last quarter. Institutional investors own 75.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Shares Sold by Cambiar Investors LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/19/eli-lilly-and-company-lly-shares-sold-by-cambiar-investors-llc.html.

Eli Lilly and Company (NYSE LLY) opened at 82.52 on Tuesday. The company has a market capitalization of $87.06 billion, a P/E ratio of 35.71 and a beta of 0.34. The firm has a 50-day moving average of $80.87 and a 200-day moving average of $82.04. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the firm earned $0.86 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 800,000 shares of company stock valued at $66,281,600 in the last quarter. 0.20% of the stock is currently owned by company insiders.

Several equities analysts have recently issued reports on the company. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet lowered Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. BMO Capital Markets reaffirmed an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a report on Wednesday, July 26th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $88.27.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.